A focus on antiarrhythmic properties of ranolazine

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 4, 2012, Pages 353-356

  Vizzardi, Enrico ^a   D'Aloia, Antonio ^a   Quinzani, Filippo ^a   Bonadei, Ivano ^a   Rovetta, Riccardo ^a   Bontempi, Luca ^a   Curnis, Antonio ^a   Dei Cas, Livio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

antiarrhythmic therapy; ranolazine

Indexed keywords

AMIODARONE; CALCIUM CHANNEL L TYPE; CHLORIDE ION; DELAYED RECTIFIER POTASSIUM CHANNEL; LIDOCAINE; PLACEBO; POTASSIUM ION; RANOLAZINE; SOTALOL;

ACUTE CORONARY SYNDROME; ANTIARRHYTHMIC ACTIVITY; CHLORIDE CURRENT; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG MECHANISM; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; SUPRAVENTRICULAR TACHYCARDIA; TORSADE DES POINTES;

ACETANILIDES; ACTION POTENTIALS; ANGINA PECTORIS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HEART ATRIA; HEART VENTRICLES; HUMANS; ION CHANNELS; MEMBRANE TRANSPORT MODULATORS; PIPERAZINES;

EID: 84868543663     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248412442000     Document Type: Review

References (24)

1. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. 2011 ; 8 (8). 1281-1290
2. Ehrlich JR, Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Curr Opin Cardiol. 2008 ; 24 (1). 50-55
3. Sossalla S, Kallmeyer B, Wagner S, et al. Altered Na+ currents in atrial fibrillation: effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010 ; 55 (21). 2330-2342
4. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007 ; 297 (16). 1775-1783
5. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007 ; 116 (15). 1647-1652
6. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008 ; 5 (7). 1019-1026
7. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010 ; 56 (15). 1216-1224
8. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007 ; 116 (13). 1449-1457
9. Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patient with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008 ; 8 (3). 175-181
10. Murdock DK, Kersten M, Kaliebe J, et al. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation. Indian Pacing Electrophysiol J. 2009 ; 9 (5). 260-267
11. Miles RH, Passman R, Murdock DK. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2011 ; 108 (5). 673-676
12. Schotten U, Verheule S, Kerfant BG, Greiser M. Enhanced late Na+ currents in atrial fibrillation: new drug target or just an epiphenomenon?. J Am Coll Cardiol. 2010 ; 55 (21). 2343-2345
13. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion. J Pharmacol Exp Ther. 2007 ; 321 (1). 213-220
14. Lemoine MD, Duverger JE, Naud P, et al. Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model. Cardiovasc Res. 2011 ; 92 (1). 67-74
15. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent. J Cardiovasc Pharmacol Therapeut. 2004 ; 9 ((suppl 1)). S65 - S83
16. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties. Circulation. 2004 ; 110 ((8)). 904-910
17. Sicouri S, Timothy KW, Zygmunt AC, et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm. 2007 ; 4 ((5)). 638-647
18. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther. 2004 ; 310 (2). 599-605
19. Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther. 2006 ; 316 (2). 718-726
20. Dhalla AK, Wang WQ, Dow J, et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2009 ; 297 (5). H1923 - H1929
21. Kloner RA, Dow JS, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. J Cardiovasc Pharm Ther. 2011 ; 16 (2). 192-196
22. Antoons G, Oros A, Beekman JD, et al. Late Na+ current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J Am Coll Cardiol. 2010 ; 55 (8). 801-809
23. CV Therapeutics 2003 :
24. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 ; 19 (12). 1289-1293